

Austrianova Facility Expansion in Singapore and Thailand

SINGAPORE, SINGAPORE, March 31, 2023 /EINPresswire.com/ -- SGAustria ("[Austrianova](#)"), a leading provider of cell biological products and services, today announced details about the expansion of its facilities in Thailand and Singapore.

The company has increased its capacity at its facility at Thailand Science Park, in Pathumthani, Thailand (metro Bangkok). This is the location where Austrianova Thailand has its state-of-the-art GMP and ISO9001:2015 qualified production suites and R&D labs. This facility focuses on the [Cell-in-a-Box](#)® cell encapsulation technology platform for protection of human and

animal cells from immune rejection and clearance when implanted in the body, as well as for long-term storage in the frozen state. Besides working together with partners and clients who use the Cell-in-a-Box® technology, the facility also produces cell banks and other cell therapy related products.


“

The increase in capacity at our two facilities reflects an increasing demand for Austrianova's signature Cell-in-a-Box® and Bac-in-a-Box® platforms”

*Walter H. Gunzburg,
Chairman*

Austrianova Singapore focuses on the [Bac-in-a-Box](#)® encapsulation technology for the protection of bacteria and yeast cells so that they can be stored at room temperature without appreciable loss in viability and also for protection from the harmful, sterilizing effects of stomach acid. Bac-in-a-Box® encapsulation is used in diverse applications such as probiotics, modification of the microbiome by selective and efficient delivery of bacteria to treat dysbiosis of the gastric tract, skin health etc.

Austrianova Singapore is also gearing up to expand its facility in Singapore for pilot scale production of Bac-in-a-Box® based bacterial and yeast products.



Cell-in-a-Box Production at Austrianova Thailand's GMP Facility

Walter H. Gunzburg, Chairman of Austrianova, said “The increase in capacity at our two facilities reflects an increasing demand for Austrianova’s signature Cell-in-a-Box® and Bac-in-a-Box® platforms.”

Austrianova CEO, Brian Salmons, added “Austrianova was awarded ISO 9001:2015 certification a year ago and we successfully completed our recent ISO 9001:2015 Quality Management System audit as well as expanding the scope of this certification going forward to reflect the breadth of our increased activities.”

About Austrianova

Austrianova (the SGAustria Group), is a biotech company with a global footprint and operations in Singapore and Thailand. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been

proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications as well as rebalancing the microbiome due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g., vaccines, antibodies, enzymes, recombinant proteins, exosomes, etc.).

Forward-Looking Statements



Austrianova Singapore's Bac-in-a-Box R&D Facility



Austrianova's Electronic GMP Control

This release includes forward-looking statements regarding Austrianova/SGAustria (the Company) and its respective businesses. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, including completion of the public offering, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks affecting the Company, economic factors and the equity markets generally. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Austrianova undertakes no obligation to publicly up-date or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. This is not an offer or solicitation to buy or sell any securities.

SOURCE Austrianova

Financial Information Contact: pierre.faddoul@square-associates.com

Company and Technology Contact: information@austrianova.com

For more information: <http://www.austrianova.com>

Brian Salmons

SGAustria/Austrianova

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/625357967>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.